Meeting the challenge of hematologic malignancies in sub-Saharan Africa

Blood

Volumn 119, Issue 22, 2012, Pages 5078-5087

  Gopal, Satish ^a,b   Wood, William A ^a   Lee, Stephanie J ^c   Shea, Thomas C ^a   Naresh, Kikkeri N ^d   Kazembe, Peter N ^e   Casper, Corey ^c,f   Hesseling, Peter B ^g   Mitsuyasu, Ronald T ^h  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e Baylor International Pediatric AIDS Initiative   (Malawi)

^f UNIVERSITY OF WASHINGTON   (United States)

^g STELLENBOSCH UNIVERSITY   (South Africa)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ASPARAGINASE; BLEOMYCIN; CARBOPLATIN; CEFTRIAXONE; CHLORAMBUCIL; CIPROFLOXACIN; CISPLATIN; CLOXACILLIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HYDROXYUREA; IFOSFAMIDE; IMATINIB; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; PACLITAXEL; PENICILLIN G; PROCARBAZINE; RITUXIMAB; TIOGUANINE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; AFRICA SOUTH OF THE SAHARA; BURKITT LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; ENDEMIC DISEASE; EPSTEIN BARR VIRUS INFECTION; FEBRILE NEUTROPENIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC VARIABILITY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KAPOSI SARCOMA; LEUKEMIA; MALARIA; MIXED INFECTION; MORBIDITY; MULTIPLE MYELOMA; NK T CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PALLIATIVE THERAPY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 84861833379     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-387092     Document Type: Review

References (99)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer- Base No. 10. http://globocan.iarc.fr. Accessed January 2, 2012.
2. Joint United Nations Program on HIV/AIDS (UNAIDS). Global HIV/AIDS response: progress report 2011. http://www.unaids.org/en/media/unaids/ contentassets/documents/unaidspublication/2011/ 20111130-UA-Report-en.pdf. Accessed January 2, 2012.
3. World Health Organization. Global tuberculosis control 2011. http://www.who.int/tb/publications/ global-report/2011/gtbr11-full.pdf. Accessed January 2, 2012.
4. World Health Organization. World Malaria Report 2010. http://www.who.int/malaria/publications/ atoz/9789241564106/en/index.html. Accessed January 2, 2012.
5. Parkin DM. The evolution of the population-based cancer registry. Nat Rev Cancer. 2006;6(8):603- 612.
6. International Agency for Research on Cancer. Cancer incidence in five continents volumes I to IX. http://ci5.iarc.fr/CI5i-ix/ci5i-ix.htm. Accessed January 2, 2012.
7. World Health Organization. WHO mortality database. http://www.who.int/ healthinfo/morttables/ en/. Accessed January 2, 2012.
8. Parkin DM, Nambooze S, Wabwire-Mangen F, Wabinga HR. Changing cancer incidence in Kampala, Uganda, 1991-2006. Int J Cancer. 2010;126(5):1187-1195.
9. Otieno MW, Remick SC, Whalen C. Adult Burkitt's lymphoma in patients with and without human immunodeficiency virus infection in Kenya. Int J Cancer. 2001;92(5):687-691. (Pubitemid 32385711)
10. Wiggill TM, Mantina H, Willem P, Perner Y, Stevens WS. Changing pattern of lymphoma sub-groups at a tertiary academic complex in a high prevalence HIV setting: a South African perspective. J Acquir Immune Defic Syndr. 2011;56(5): 460-466.
11. Kaaya EE, Castaños-Velez E, Ekman M, et al. AIDS and non-AIDS-related malignant lymphoma in Tanzania. Afr Health Sci. 2006;6(2):69-75. (Pubitemid 47023157)
12. Patel M, Philip V, Fazel F. Human immunodeficiency virus infection and Hodgkin's lymphoma in South Africa: an emerging problem. Adv Hematol. 2011;2011:578163.
13. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118(12):3030-3044.
14. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008; 148(10):728-736. (Pubitemid 351717418)
15. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20(12): 1645-1654. (Pubitemid 44162407)
16. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59-67. (Pubitemid 47017468)
17. Mbulaiteye SM, Katabira ET, Wabinga H, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer. 2006;118(4):985-990. (Pubitemid 43157675)
18. Sasco AJ, Jaquet A, Boidin E, et al. The challenge of AIDS-related malignancies in sub- Saharan Africa. PLoS One. 2010;5(1):e8621.
19. + T-cell lymphocytes. Blood. 2011; 117(23):6100-6108.
20. Simard EP, Engels EA. Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis. 2010;51(8):957-962.
21. Bonnet F, Burty C, Lewden C, et al. Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis. 2009; 48(5):633-639.
22. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50(10):1387-1396.
23. Engels EA, Pfeiffer RM, Landgren O, Moore RD. Immunologic and virologic predictors of AIDS-related non-Hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr. 2010;54(1):78-84.
24. Guiguet M, Boué F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;10(12):1152-1159.
25. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(12):2551-2559.
26. Lanoy E, Rosenberg PS, Fily F, Lascaux AS, et al. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood. 2011;118(1):44-49.
27. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108(12):3786-3791. (Pubitemid 44864560)
28. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793-800.
29. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2010 revision. http://whqlibdoc.who.int/publications/ 2010/9789241599764-eng.pdf. Accessed January 2, 2012.
30. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adolescents and adults. http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed January 2, 2012.
31. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society- USA panel. JAMA. 2010;304(3):321-333.
32. Mwakigonja AR, Kaaya EE, Heiden T, et al. Tanzanian malignant lymphomas: WHO classification, presentation, ploidy, proliferation and HIV/ EBV association. BMC Cancer. 2010;10:344.
33. Bateganya MH, Stanaway J, Brentlinger PE, et al. Predictors of survival after a diagnosis of non-Hodgkin lymphoma in a resource-limited setting: a retrospective study on the impact of HIV infection and its treatment. J Acquir Immune Defic Syndr. 2011;56(4):312-319.
34. Naresh KN, Raphael M, Ayers L, et al. Lymphomas in sub-Saharan Africa: what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research? Br J Haematol. 2011;154(6):696-703.
35. Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non- Hodgkin lymphoma. Blood. 2010;115(15):3008- 3016.
36. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS. 2009;23(15):2029- 2037.
37. Berenguer J, Miralles P, Ribera JM, et al. Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47(4):422-428. (Pubitemid 351366959)
38. Chao C, Xu L, Abrams D, et al. Survival of non- Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS. 2010;24(11):1765-1770.
39. Orem J, Mulumba Y, Algeri S, et al. Clinical characteristics, treatment and outcome of childhood Burkitt's lymphoma at the Uganda Cancer Institute. Trans R Soc Trop Med Hyg. 2011;105(12): 717-726.
40. Mwanda WO, Orem J, Fu P, et al. Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. J Clin Oncol. 2009;27(21):3480-3488.
41. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004;350(13):1328- 1337.
42. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343(7):481-492. (Pubitemid 30646489)
43. Biggar RJ, Henle W, Fleisher G, Böcker J, Lennette ET, Henle G. Primary Epstein-Barr virus infections in African infants: I. Decline of maternal antibodies and time of infection. Int J Cancer. 1978;22(3):239-243. (Pubitemid 9024589)
44. Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res. 2009;143(2):209-221.
45. Kafuko GW, Burkitt DP. Burkitt's lymphoma and malaria. Int J Cancer. 1970;6(1):1-9.
46. Geser A, Brubaker G, Draper CC. Effect of a malaria suppression program on the incidence of African Burkitt's lymphoma. Am J Epidemiol. 1989;129(4):740-752. (Pubitemid 19094252)
47. Carpenter LM, Newton R, Casabonne D, et al. Antibodies against malaria and Epstein-Barr virus in childhood Burkitt lymphoma: a case-control study in Uganda. Int J Cancer. 2008;122(6):1319- 1323.
48. Mutalima N, Molyneux E, Jaffe H, et al. Associations between Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results from a case-control study. PLoS One. 2008;3(6):e2505.
49. Guech-Ongey M, Yagi M, Palacpac NM, et al. Antibodies reactive to Plasmodium falciparum serine repeat antigen in children with Burkitt lymphoma from Ghana. Int J Cancer. 2012;130(8): 1908-1914.
50. Lam KM, Syed N, Whittle H, Crawford DH. Circulating Epstein-Barr virus-carrying B cells in acute malaria. Lancet. 1991;337(8746):876-878.
51. Chêne A, Donati D, Guerreiro-Cacais AO, et al. A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog. 2007;3(6):e80.
52. Ogwang MD, Bhatia K, Biggar RJ, Mbulaiteye SM. Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. Int J Cancer. 2008;123(11):2658-2663.
53. Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med. 1996; 2(8):925-928.
54. Engels EA, Atkinson JO, Graubard BI, et al. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis. 2007;196(2): 199-207. (Pubitemid 47047458)
55. Casper C, Carrell D, Miller KG, et al. HIV serodis-cordant sex partners and the prevalence of human herpesvirus 8 infection among HIV negative men who have sex with men: baseline data from the EXPLORE Study. Sex Transm Infect. 2006; 82(3):229-235. (Pubitemid 43901593)
56. Mayama S, Cuevas LE, Sheldon J, et al. Prevalence and transmission of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents. Int J Cancer. 1998;77(6):817-820. (Pubitemid 28378125)
57. Engels EA, Mbulaiteye SM, Othieno E, et al. Kaposi sarcoma-associated herpesvirus in non- Hodgkin lymphoma and reactive lymphadenopathy in Uganda. Hum Pathol. 2007;38(2):308-314. (Pubitemid 46110846)
58. World Bank. Agriculture and rural development. http://data.worldbank.org/ topic/agriculture-and-rural- development. Accessed January 2, 2012.
59. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2011. http://www.cibmtr.org. Accessed January 2, 2012.
60. International Atomic Energy Agency. Directory of radiotherapy centers, 2011. http://www-naweb. iaea.org/nahu/dirac/. Accessed January 2, 2012.
61. Benediktsson H, Whitelaw J, Roy I. Pathology services in developing countries: a challenge. Arch Pathol Lab Med. 2007;131(11):1636-1639. (Pubitemid 350077458)
62. Awadelkarim KD, Mohamedani AA, Barberis M. Role of pathology in sub-Saharan Africa: an example from Sudan. Pathol Lab Med Int. 2010;2: 49-57.
63. American Medical Association. Physician Characteristics and Distribution in the US (2011 Ed). Washington, DC: American Medical Association; 2011.
64. World Health Organization. WHO model lists of essential medicines. http://www.who.int/medicines/ publications/essentialmedicines/en/index.html. Accessed January 2, 2012.
65. Kiarie GW, Othieno-Abinya NA, Riyat MS. The GLIVEC international patient assistance programme: the Nairobi experience. East Afr Med J. 2009;86(12 suppl):S106-S107.
66. United Nations. MDG Gap Task Force Report 2011. http://www.who.int/ medicines/mdg/en/index. html. Accessed January 2, 2012.
67. Farmer P, Frenk J, Knaul FM, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010; 376(9747):1186-1193.
68. Barton MB, Frommer M, Shafiq J. Role of radio-therapy in cancer control in low-income and middle-income countries. Lancet Oncol. 2006; 7(7):584-595. (Pubitemid 43923676)
69. Salminen EK, Kiel K, Ibbott GS, et al. International Conference on Advances in Radiation Oncology (ICARO): outcomes of an IAEA meeting. Radiat Oncol. 2011;6:11.
70. Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303(16):1617-1624.
71. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy- sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333(23):1540-1545.
72. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051-1054. (Pubitemid 23114397)
73. McDiarmid S, Hutton B, Atkins H, et al. Performing allogeneic and autologous hematopoietic SCT in the outpatient setting: effects on infectious complications and early transplant outcomes. Bone Marrow Transplant. 2010;45(7):1220-1226.
74. Michieli M, Mazzucato M, Tirelli U, De Paoli P. Stem cell transplantation for lymphoma patients with HIV infection. Cell Transplant. 2011;20(3): 351-370.
75. Wu CY, Hu HY, Pu CY, et al. Aerodigestive tract, lung and haematological cancers are risk factors for tuberculosis: an 8-year population-based study. Int J Tuberc Lung Dis. 2011;15(1):125-130.
76. Stefan DC, Kruis AL, Schaaf HS, Wessels G. Tuberculosis in oncology patients. Ann Trop Paediatr. 2008;28(2):111-116.
77. Allegranzi B, Bagheri Nejad S, Combescure C, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011;377(9761): 228-241.
78. Aiken AM, Mturi N, Njuguna P, et al. Risk and causes of paediatric hospital-acquired bacteraemia in Kilifi District Hospital, Kenya: a prospective cohort study. Lancet. 2011;378(9808):2021-2027.
79. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93.
80. Dippenaar A, Wessels G, Hesseling PB. Improved outcome in South African children of mixed ethnicity treated for ALL. Pediatr Hematol Oncol. 2006;23(4):329-338.
81. Israëls T, van de Wetering MD, Hesseling P, van Geloven N, Caron HN, Molyneux EM. Malnutrition and neutropenia in children treated for Burkitt lymphoma in Malawi. Pediatr Blood Cancer. 2009;53(1):47-52.
82. Rowe JS, Shah SS, Motlhagodi S, et al. An epidemiologic review of enteropathogens in Gaborone, Botswana: shifting patterns of resistance in an HIV endemic region. PLoS One. 2010;5(6): e10924.
83. Brooks JT, Ochieng JB, Kumar L, et al. Surveillance for bacterial diarrhea and antimicrobial resistance in rural western Kenya, 1997-2003. Clin Infect Dis. 2006;43(4):393-401. (Pubitemid 44157144)
84. Tapko J, Mainuka, P, Diarra-Nama AJ. Status of blood safety in the WHOAfrican region: report of the 2006 survey. http://www.afro.who.int/en/ clusters-a-programmes/hss/blood-safety-laboratories- a-health-technology.html. Accessed January 2, 2012.
85. Bloch EM, Vermeulen M, Murphy E. Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges. Transfus Med Rev. 2012;26(2):164-180.
86. Harding R, Higginson IJ. Palliative care in sub- Saharan Africa. Lancet. 2005;365(9475):1971- 1977.
87. World Health Organization. A community health approach to palliative care for HIV and cancer patients in Africa. http://www.who.int/cancer/ palliative/africanproject/en/index.html. Accessed January 2, 2012.
88. Harif M, Barsaoui S, Benchekroun S, et al. Treatment of B-cell lymphoma with LMB modified protocols in Africa: report of the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer. 2008;50(6):1138-1142. (Pubitemid 351555534)
89. Traoré F, Coze C, Atteby JJ, et al. Cyclophosphamide monotherapy in children with Burkitt lymphoma: a study from the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer. 2011;56(1):70-76.
90. Hesseling PB, Njume E, Kouya F, et al. The Cameroon 2008 Burkitt lymphoma protocol: improved event-free survival with treatment adapted to disease stage and the response to induction therapy. Pediatr Hematol Oncol. 2012;29(2):119- 129.
91. Lemerle J, Barsaoui S, Harif M, et al. Treatment of childhood cancer in Africa: action of the Franco-African childhood cancer group. Med Trop (Mars). 2007;67(5):497-504. (Pubitemid 350157176)
92. Hunger SP, Sung L, Howard SC. Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low-income countries: a proposal. Pediatr Blood Cancer. 2009;52(5):559-565.
93. Naresh KN, Ibrahim HA, Lazzi S, et al. Diagnosis of Burkitt lymphoma using an algorithmic approach: applicable in both resource-poor and resource- rich countries. Br J Haematol. 2011; 154(6):770-776.
94. Rottinghaus EK, Ugbena R, Diallo K, et al. Dried blood spot specimens are a suitable alternative sample type for HIV-1 viral load measurement and drug resistance genotyping in patients receiving first-line antiretroviral therapy. Clin Infect Dis. 2012;54(8):1187-1195.
95. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011; 377(9776):1495-1505.
96. Clinton Health Access Initiative. Antiretroviral (ARV) ceiling price list. http://www.clintonfoundation. org/files/chai-arv-ceilingPriceList-201105- english.pdf. Accessed March 13, 2012.
97. Beaulieu N, Bloom D, Bloom R, Stein R. Breakaway: the global burden of cancer - challenges and opportunities. A report from the Economist Intelligence Unit. http://livestrongblog.org/GlobalEconomicImpact. pdf. Accessed January 10, 2012.
98. Joint United Nations Program on HIV/AIDS (UNAIDS). UNAIDS report on the global AIDS epidemic 2010. http://www.unaids.org/globalreport/ Global-report.htm. Accessed January 12, 2012.
99. Sanne I, Orrell C, Fox MP, et al. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010; 376(9734):33-40.